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Abstract The autism spectrum disorders (ASD) have a
significant hereditary component, but the implicated genetic
loci are heterogeneous and complex. Consequently, there is
a gap in understanding how diverse genomic aberrations all
result in one clinical ASD phenotype. Gene expression
studies from autism brain tissue have demonstrated that
aberrantly expressed protein-coding genes may converge
onto common molecular pathways, potentially reconciling
the strong heritability and shared clinical phenotypes with
the genomic heterogeneity of the disorder. However, the
regulation of gene expression is extremely complex and
governed by many mechanisms, including noncoding
RNAs. Yet no study in ASD brain tissue has assessed for
changes in regulatory long noncoding RNAs (lncRNAs),
which represent a large proportion of the human transcriptome,
and actively modulate mRNA expression. To assess if aberrant
expression of lncRNAs may play a role in the molecular
pathogenesis of ASD, we profiled over 33,000 annotated
lncRNAs and 30,000 mRNA transcripts from postmortem
brain tissue of autistic and control prefrontal cortex and cere-
bellum by microarray. We detected over 200 differentially
expressed lncRNAs in ASD, which were enriched for genomic
regions containing genes related to neurodevelopment and
psychiatric disease. Additionally, comparison of differences
in expression of mRNAs between prefrontal cortex and cere-
bellum within individual donors showed ASD brains had
more transcriptional homogeneity. Moreover, this was
also true of the lncRNA transcriptome. Our results sug-
gest that further investigation of lncRNA expression in
autistic brain may further elucidate the molecular patho-
genesis of this disorder.
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Introduction
The autism spectrum disorders (ASD) are one of the most
heritable of the common neuropsychiatric conditions (Miles
2011). However, there are hundreds of implicated genomic
loci with heterogeneous functions (Holt and Monaco 2011).
As a result, there is difficulty in understanding how this
diverse genetic susceptibility translates to a common clinical
phenotype. Multiple gene expression studies in postmortem
autism brain tissue suggest that aberrant processing of the
mRNA transcriptome in autistic brains may provide a mech-
anistic convergence between this diverse genetic heritability
and disruption of fundamental neurodevelopmental path-
ways leading to the common ASD phenotype (Geschwind
2008). For example, three transcription studies in autism
brain tissue have demonstrated convergence of differentially
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expressed genes in autism brains on immune and synapse
formation pathways (Purcell et al. 2001; Garbett et al. 2008;
Voineagu et al. 2011). Similarly, gene expression studies in
other tissue types from autism patients suggest a conver-
gence of differentially expressed mRNAs on similar funda-
mental molecular pathways (Lintas et al. 2012; Voineagu
2012). However, the regulation (and consequently dysregu-
lation) of gene expression is a very complex process, result-
ing from an interplay of DNA sequence variation, chromatin
and epigenetic modifications, protein transcription factors,
and regulatory noncoding RNAs.
While transcriptome studies in autistic brain samples
have demonstrated that aberrant expression of mRNA tran-
scripts may represent a convergence of the heterogeneous
genomics of ASD, none of these studies have concurrently
assessed the regulatory RNAs that may underlie aberrant
mRNA expression. Three studies in lymphoblast cell lines
from autism patients have shown that miRNAs are abnormal
in autism (Talebizadeh et al. 2008; Sarachana et al. 2010;
Seno et al. 2011), and Abu-Elneel et al. demonstrated dif-
ferential expression of miRNAs in autistic cerebellum (Abu-
Elneel et al. 2008). However, a novel class of regulatory
RNAs, long noncoding RNAs (lncRNAs), has recently been
implicated in a number of fundamental gene regulatory
events, but their role in autism molecular pathogenesis
remains unknown.
Long noncoding RNAs are defined as RNAs greater than
200 nucleotides in length (as compared to ~21–23 nucleo-
tide length of miRNAs), which do not encode for protein.
While originally thought to be “transcriptional noise,” long
noncoding RNAs have been shown to be involved in major
mechanisms of gene expression regulation, such as targeting
transcription factors, initiating chromatin remodeling,
directing methylation complexes, and blocking nearby tran-
scription (Ponting et al. 2009). Moreover, pervasive tran-
scription of lncRNAs has been demonstrated to occur in
both a temporally and spatially regulated manner during
development (Amaral and Mattick 2008), with the central
nervous system displaying the greatest abundance of tran-
scribed lncRNAs (Mercer et al. 2008). So, while there have
been multiple studies at the transcriptome level in autism
demonstrating aberrant expression of mRNAs, none have
assessed long noncoding RNAs, which are increasingly
recognized as a fundamental to gene expression regulation.
Therefore, the purpose of this study was to determine if
dysregulated expression of lncRNAs might play a role in the
molecular pathogenesis of ASD. To do so, we profiled over
33,000 annotated lncRNAs in ASD patient postmortem
brain tissue (prefrontal cortex and cerebellum) using micro-
arrays. In parallel, we also assessed for transcriptional dif-
ferences in all known protein-coding mRNAs. We identified
over 200 differentially expressed lncRNAs, which were
oriented in or around protein-coding loci strongly enriched
for brain development genes. Moreover, we discovered that
the previously reported homogeneity of mRNA transcrip-
tion within autism brains is also observed within the
lncRNA component of the transcriptome.
Materials and Methods
Brain Tissue
Human postmortem brain tissue was obtained from the
NICHD Brain and Tissue Bank for Developmental Disor-
ders at the University of Maryland, Baltimore, MD, USA.
The collection protocol at the University of Maryland, Bal-
timore was reviewed and approved by the Institutional Re-
view Board of the University of Maryland, Baltimore. The
clinical characteristics of the patients from whom tissue was
derived are shown in the Supplementary Data—Additional
File 1, Table 1. Both the prefrontal cortex and cerebellum
samples were obtained from two autism patients and two
age- and sex-matched controls (total biological replicates of
n04 for autism and controls).
RNA Isolation and Quality Control
Total RNAwas extracted by homogenizing samples in TRI-
zol® Reagent (Invitrogen) according to the manufacturer’s
protocol. RNA quantity was measured by NanoDrop ND-
1000. Agilent Bioanalyzer 2100 was used to assess RNA
integrity for each sample (Supplementary Data—Additional
File 1, Table 1).
lncRNA Microarray
ArrayStar, Inc (Rockville, MD, USA) Human lncRNA
Microarray V2.0 was used and run by the service provider.
The array contains 33,045 lncRNAs and 30,215 protein-
coding transcripts. The lncRNAs were manually collected
from the most authoritative databases such as RefSeq,
UCSC knowngenes, Ensembl, and manually curated lncRNA
literature sources (Supplementary Data—Additional File 1,
Table 2). The mRNAs were obtained from RefSeq (March
2011). Each transcript was represented by a specific exon or
splice junction probe. Positive probes for housekeeping genes
and negative control probes (i.e., scramble sequences) were
also printed onto the array for hybridization quality control.
Microarray Labeling, Hybridization, and Scanning
Sample labeling and array hybridization were performed
according to the Agilent One-Color Microarray-Based Gene
Expression Analysis protocol (Agilent Technology) with
minor modifications. Briefly, mRNA was purified from
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1 μg total RNA after removal of rRNA (mRNA-ONLY™
Eukaryotic mRNA Isolation Kit, Epicentre). Then, each sam-
ple was amplified and transcribed into fluorescent cRNA
along the entire length of the transcripts without 3′ bias utiliz-
ing a random priming method. The labeled cRNAs were
purified by RNAeasy Mini Kit (Qiagen). The concentration
and specific activity of the labeled cRNAs (picomole of Cy3/
microgram of cRNA) weremeasured byNanoDropND-1000.
One microgram of each labeled cRNA was fragmented by
adding 11 μl of 10× blocking agent and 2.2 μl of 25× frag-
mentation buffer, heating the mixture at 60 °C for 30min, then
adding 55 μl of 2× GE hybridization buffer to dilute the
labeled cRNA. One hundred microliters of hybridization so-
lutionwas dispensed into the gasket slide and assembled to the
lncRNA expression microarray slide. The slides were incu-
bated for 17 h at 65 °C in an Agilent Hybridization Oven. The
hybridized arrays were washed, fixed, and scanned using the
Agilent DNA Microarray Scanner (G2505B).
Microarray Data Processing
Agilent Feature Extraction software (version 10.5.1.1) was
used to analyze acquired array images. Quantile normaliza-
tion and subsequent data processing were performed using
the GeneSpring GX v11.5.1 software package (Agilent
Technologies). After quantile normalization of the raw data,
lncRNAs and mRNAs with at least four out of eight samples
flagged as 'present' or 'marginal' were chosen for further
analysis. Differentially expressed lncRNAs and mRNAs
were identified through fold change filtering. Differentially
expressed lncRNAs and mRNAs with statistical signifi-
cance (as determined by two-tailed Student’s t test<0.05)
were identified through volcano plot filtering. All micro-
array data were deposited into Gene Expression Omnibus
(GEO) at the National Center for Biotechnology Informa-
tion, NIH under Series Number GSE36315.
qRT-PCR
Five randomly selected lncRNAs from among those show-
ing the greatest fold change were chosen for confirmation
via quantitative real-time reverse transcriptase PCR (qRT-
PCR). The selected lncRNAs and the primers used for qRT-
PCR are shown in Supplementary Data—Additional File 1,
Table 3. Five micrograms of total RNA was used for the
synthesis of first strand cDNA using the SuperScript III First
Strand cDNA Synthesis Kit (Invitrogen). qRT-PCR analysis
was performed using ABI prism 7900 (Applied Biosystems)
with SYBR Green expression assay system (Applied Biosys-
tems). Normalized, relative gene expression was calculated
using standard ΔΔCt methods using Applied Biosystem RQ
Manager Software (v1.2). Each qPCR reaction was run three
separate times, with technical triplicates in each reaction.
In Silico Mapping Analysis
To assess for the potential cis-regulatory effects of the
identified lncRNAs, we utilized the Genomic Regions En-
richment of Annotations Tool (Mclean et al. 2010). This
program takes genomic coordinates as inputs and outputs
nearby genes and their ontologies. Default settings were
used for analysis on all probes detected as differentially
expressed between ASD and Ctrl (both prefrontal cortex
and cerebellum), with curated regulatory domains included.
Gene Ontology Enrichment Analysis
To assess for functional categories that the genes we identified
as significantly differentially expressed in ASD implicated,
we used the Database for Annotation, Visualization and Inte-
grated Discovery v6.7, accessed at http://david.abcc.ncifcrf.
gov/. GO categories were reported as significant only if the p
value after multiple testing corrections was <0.05.
Results
In total, we detected 222 lncRNAs differentially expressed
between ASD and control samples (fold change>2, p<0.05).
Eighty-two of these were unique to the prefrontal cortex, and
143 were unique to the cerebellum (Fig. 1). The majority of
differentially expressed lncRNAs in ASD were from inter-
genic regions (~60 %), antisense to protein-coding loci
(~15 %), or within introns of protein-coding genes (~10 %),
with the others representing overlapping transcripts from
exons or introns in both sense and antisense directions. This
distribution was not significantly different from the distribu-
tion of all lncRNAs detected by the array (Supplementary
Data—Additional File 1, Fig. 1).We confirmed a select number
of the most highly differentially expressed lncRNAs between
autism and controls by qRT-PCR analysis (Supplementary
Data—Additional File 1, Fig. 2).
Almost 50 % of differentially expressed lncRNAs map to
within 50 kilobases (kb) of an annotated gene, and greater
than 90 % map within 500 kb of a known gene (Supple-
mentary Data—Additional File 1, Fig. 3). Mapping all dif-
ferentially expressed lncRNAs to the nearest genes
identified 381 protein-coding loci under putative cis-regula-
tory control by these lncRNAs. The ontologies of those loci
implicated two functions: cerebral cortex cell migration and
targets of microRNAs mir-103/107 (Table 1). These results
are intriguing given that the prevailing cellular model of
autism is a defect in neuronal connectivity (Geschwind
and Levitt 2007) and that mir-103/107 has previously been
implicated in CNS development (Moncini et al. 2011),
Alzheimer’s disease (Nelson and Wang 2010), and schizo-
phrenia (Santarelli et al. 2011). Eleven of these genes near
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differentially expressed lncRNAs have previously been im-
plicated in ASD, and 18 have previously been shown to
exhibit differential expression in ASD brain (Supplementary
Data—Additional File 1, Table 4).
Ninety of the differentially expressed lncRNAs are oriented
in or around a known protein-coding region (i.e., not inter-
genic). Of these, three are known imprinted loci in humans
(C9orf85, SLC4A2, and UBE3A). Interestingly, UBE3A is
implicated in the genomic imprinting disorder Angelman
syndrome, which shares many features with ASD (Bonati et
al. 2007). Surprisingly, however, only 3 of these 90 genes are
also differentially expressed (RBM8a, ARL17A, and KLF6),
suggesting perhaps more complex mechanisms for many of
these lncRNAs than simple cis-regulation.
Our array also contained probes for known protein-coding
transcripts, of which we detected 355 genes differentially
expressed between ASD and controls, which were enriched
for the process of alternative splicing (Supplementary Data—
Additional File 1, Table 5). This finding is in agreement with a
recent large transcriptome study in autistic brains by Voineagu
et al., where they demonstrated dysregulated splicing of
A2BP1-dependent exons in ASD brains using RNA-seq (Voi-
neagu et al. 2011).
Because our samples from the prefrontal cortex and cere-
bellum were from the same patients, we also had the ability to
compare intra-individual differences in expression of both
genes and lncRNAs between these regions. We detected al-
most 2,000 genes differentially expressed in the control pre-
frontal cortex versus the control cerebellum, which were
highly enriched for gene ontology terms related to synapto-
genesis (Supplementary Data—Additional File 1, Table 6),
but only 322 genes differentially expressed between the ASD
prefrontal cortex and cerebellum (Fig. 1). These results are
also in agreement with the study by Voineagu and colleagues,
where they observed more transcriptional homogeneity in
ASD brains (Voineagu et al. 2011). In light of this, then, we
were intrigued to find that the number of lncRNAs differen-
tially expressed within control brains was also much greater
than lncRNAs differentially expressed within autism brains
(1,375 lncRNAs versus 236 lncRNAs, respectively).
Fig. 1 Summary of
differentially expressed
lncRNAs and mRNAs.
Asterisk, three shared lncRNAs;
caret, 99 shared lncRNAs
Table 1 Gene ontology analysis of 381 mRNA loci nearby differentially expressed lncRNAs








GO biological Process Cerebral cortex cell migration 3.16e−2 4.68 2.06e−2 12.82
MSigDB miRNA motifs Targets of miR-103/miR-107 5.88e−8 3.18 3.85e−2 3.30
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Discussion
While there have been multiple studies of the mRNA tran-
scriptome in ASD, we report here the first assessment of
regulatory lncRNAs in autism postmortem brain tissue. We
identified lncRNAs that are differentially expressed in ASD
brain tissue and showed that they are enriched for genomic
loci involved in neurodevelopment and psychiatric disease.
Notably, trans-regulatory mechanisms of these lncRNAs are
likely to be major contributors to their cellular importance.
Future studies using knockdown or overexpression techni-
ques in a relevant model system would be a reasonable
approach to uncover potential trans-regulatory effects.
Furthermore, both the lncRNA and the mRNA transcrip-
tome appear to be more differentially expressed within control
brains (between prefrontal cortex and cerebellum) as com-
pared to ASD brains. This finding is particularly interesting
in the context of imaging studies of autistic brain, where it has
been suggested that anatomically distinct regions of the autis-
tic brain are less specialized from each other than in healthy
subjects (Minshew and Keller 2010). It is intriguing to spec-
ulate that perhaps less “genomic differentiation” between
brain regions in autism underlies these imaging findings.
In summary, these results identify lncRNAs that are aber-
rantly expressed in autistic brain and suggest that perhaps
lncRNAs contribute to dysregulation of protein-coding loci in
ASD and/or that a fundamental defect in genome-wide tran-
scriptional regulation—including noncoding regions of the ge-
nome—underlies ASD molecular pathology. Future studies
will need to replicate and expand these findings in more patient
samples, but this initial evidence suggests that the lncRNA
component of the transcriptome deserves attention in autism.
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